证券代码：688177 证券简称：百奥泰 公告编号：2026-001 百奥泰生物制药股份有限公司 自愿披露关于与 Hikma Pharmaceuticals USA Inc.就 BAT2206（乌司奴单抗）注射液签署授权许可与商业 化协议收到里程碑付款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于 2021 年 8 月 27 日召开公司第一届董事会第二十六次会议，审议通过了《关于公司与 Hikma Pharmaceuticals USA Inc.就 BAT2206（乌司奴单抗）注射液签署许可与 商业化协议的议案》，本次签署授权协议事项不属于关联交易和重大资产重组事 项，根据《上海证券交易所科创板股票上市规则》及公司章程等相关规定，本 议案无需提交股东大会审议。公司于同日与 Hikma Pharmaceuticals USA Inc. （以下简称"Hikma"）签署授权许可与商业化协议，将公司的 BAT2206（乌司 奴单抗）注射液在美国市场的独占的产品商 ...

百奥泰1月9日公告，公司于2021年8月27日与Hikma Pharmaceuticals USA Inc.签署授权许可与商业化协 议，将BAT2206（乌司奴单抗）注射液在美国市场的独占产品商业化权益有偿许可给Hikma。根据协 议，百奥泰于近日收到Hikma支付的1000万美元里程碑付款。该笔款项将进一步充盈公司现金储备，为 后续管线研发和国际化战略推进提供助力。BAT2206注射液已获美国FDA和欧洲EMA批准上市，并向 国家药品监督管理局提交上市申请，目前正在评审中。 ...

Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a significant increase in price and trading activity, indicating positive market sentiment despite some fluctuations in recent months [1][2]. - As of January 9, Baiotai's stock price rose by 2.03% to 25.08 CNY per share, with a total market capitalization of 10.385 billion CNY [1]. - The company has experienced an 8.38% increase in stock price year-to-date, with a 5.82% increase over the past 20 days, although it has seen a 7.11% decline over the last 60 days [2]. Group 2 - Baiotai's main business involves the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2]. - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, reflecting a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a 38.72% increase in losses compared to the previous year [2]. - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts such as biomedicine and cancer treatment [2].

Group 1 - The core viewpoint is that domestic innovative drugs are increasingly gaining global application, with growing brand influence and trust [1] - Baiyao Tai Biopharmaceutical Co., Ltd. has developed Adalimumab injection, which is set to be approved for sale in the UK by September 2025, marking it as the first domestically approved biosimilar of Adalimumab [1] - Guangzhou Development Zone and Huangpu District have established over 4,800 biopharmaceutical companies, achieving at least one innovative drug approval annually for five consecutive years, ranking fifth in national competitiveness [2] Group 2 - Yipin Hong Pharmaceutical Group has over ten global innovative drug projects in development, including the gout drug AR882, which is expected to complete its Phase III clinical trials by the end of 2025 [2] - Ranstone Medical has received approval for its breast cancer targeted drug Capecitabine companion diagnostic kit in Japan by September 2025, marking a significant milestone in China's precision medicine for breast cancer [2] - Ranstone Medical has established partnerships with over 140 innovative drug companies and is involved in 15 companion diagnostic projects, enhancing its capabilities in core detection technology and data analysis [3] Group 3 - The National Technology Transfer and Transformation Center (Guangdong-Hong Kong-Macao Greater Bay Area) Biopharmaceutical Sub-center has begun construction, selecting 159 quality projects from 664 submissions, covering key areas like cell therapy and AI drug development [3][4] - The "One Island, Multiple Parks" model has been initiated at the Biopharmaceutical Island, promoting resource complementarity and activating regional development [5]

Core Viewpoint - Baiotai (688177.SH) is currently trading at 23.99 yuan, reflecting a decline of 1.28% and is in a state of share price drop since its IPO [1] Group 1: Company Overview - Baiotai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 21, 2020, with an initial offering price of 32.76 yuan per share [1] - The company issued 60 million shares during its IPO, with China International Capital Corporation as the sponsor and representatives being Xie Xianming and Zhao Zeyu, while GF Securities and Morgan Stanley Huaxin Securities acted as joint lead underwriters [1] Group 2: IPO Financials - On its first day of trading, Baiotai reached an intraday high of 78.00 yuan per share [1] - The total funds raised from the IPO amounted to 1.966 billion yuan, with a net amount of 1.876 billion yuan after deducting issuance costs, which was 124 million yuan less than the original plan of 2 billion yuan [1] - The total issuance costs for the IPO were 89.4002 million yuan, with 77.8302 million yuan paid to the sponsor and joint lead underwriters [1]

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Group 1: Economic Development and Innovation - The provincial secretary emphasizes the need for Guangzhou to implement the spirit of the 20th Central Committee and the Central Economic Work Conference, aiming for a strong start in the 14th Five-Year Plan [1][4] - The focus is on enhancing the low-altitude economy through advancements in unmanned aerial vehicle technology, with encouragement for companies to innovate and expand into diverse application scenarios [1] - The biopharmaceutical sector is highlighted as a key area for development, with a call for effective technology transfer and innovation mechanisms to improve product supply and market demand matching [2] Group 2: Public Safety and Governance - The provincial secretary inspects public transportation safety measures during the New Year holiday, emphasizing the importance of maintaining public order and safety in crowded areas [3] - There is a strong focus on collaborative efforts among various departments to ensure the safety and convenience of citizens and tourists during peak times [3] Group 3: Urban Development and Modernization - The need for Guangzhou to explore new paths for modern urban governance is stressed, with an emphasis on integrating historical preservation with urban quality improvement [4] - The city is encouraged to adopt a people-centered approach in urban planning and management, aiming for coordinated regional development and urban renewal [4]

本报讯 （记者王镜茹）12月30日晚，百奥泰生物制药股份有限公司（以下简称"百奥泰"）发布公告称，公司已于近日收到 合作伙伴Sandoz AG（以下简称"Sandoz"）支付的450万美元里程碑付款。此笔款项源于双方此前就BAT1706（贝伐珠单抗）注 射液签署的授权许可与商业化协议。 公告显示，该笔450万美元里程碑付款的到账，进一步充实了公司的现金储备，将为后续管线研发及国际化战略的推进提 供资金支持。 回溯此前合作，百奥泰于2021年9月8日与Sandoz达成协议，将BAT1706在美国、欧洲、加拿大及大部分其他未覆盖国际市 场的排他性产品商业化权益有偿许可给Sandoz。 根据当时签署的协议条款，该项合作的首付款及里程碑款总金额最高可达1.55亿美元，其中包括2750万美元的首付款、累 计不超过1.275亿美元的里程碑付款，以及两位数百分比的利润分成。 （编辑 张伟） ...

百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于 2021 年 9 月 8 日召开公司第一届董事会第二十七次会议，审议通过了《关于 BAT1706（贝 伐珠单抗）注射液签署授权许可与商业化协议的议案》，本次签署授权协议事项 不属于关联交易和重大资产重组事项，根据《上海证券交易所科创板股票上市规 则》及公司章程等相关规定，本议案无需提交股东大会审议。 自愿披露关于与 Sandoz AG 就 BAT1706（贝伐珠单 抗）注射液签署授权许可与商业化协议收到里程碑付 款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于北京时间 2021 年 9 月 8 日与 Sandoz AG（以下简称"Sandoz"）签署授 权许可与商业化协议，将公司的 BAT1706（贝伐珠单抗）注射液在美国、欧洲、 加拿大和大部分其它 BAT1706 合作未覆盖的国际市场的排他的产品商业化权益 有偿许可给 Sandoz（以下简称"协议"或"本协议"）。首付款及里程碑款总金额最 高至 1.55 亿美元，其中包括 2,750 万美 ...

公司于 2025 年 12 月 30 日收到立信出具的《关于变更百奥泰生物制药股份 有限公司 2025 年年报审计质量控制复核人的告知函》，具体情况如下： 证券代码：688177 证券简称：百奥泰 公告编号：2025-073 百奥泰生物制药股份有限公司 关于变更项目质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 百奥泰生制药股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日和 2025 年 4 月 30 日分别召开了第二届董事会第二十四次会议和 2024 年年度股东大会， 审议通过了《关于续聘 2025 年度会计师事务所的议案》，同意续聘立信会计师事 务所（特殊普通合伙）（以下简称"立信"）为公司 2025 年度会计师事务所。 具体内容详见公司于 2025 年 4 月 9 日在上海证券交易所网站（www.sse.com.cn） 披露的《百奥泰生物制药股份有限公司关于续聘会计师事务所的公告》（公告编 号：2025-030）。 本次变更的项目质量控制复核人不存在违反《中国注册会计师职业道德 ...